Cytek Biosciences, Inc. Liquidation Value

CTKB Other

Cash & Equivalents

$90.85M
As of 2025-12-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $90.85M
Total Obligations: -$95.25M
$-4.40M
Per share: $-0.03
Period: 2025-12-31

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $90.85M
AR: $62.51M
Total Obligations: -$95.25M
$58.11M
Per share: $0.45
Period: 2025-12-31

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $90.85M
AR: $62.51M
Inventory: $48.43M
Total Obligations: -$95.25M
$106.54M
Per share: $0.83
Period: 2025-12-31

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-4.40M$-0.03
Liquid Liquidation Value$58.11M$0.45
Operating Liquidation Value$106.54M$0.83

Key Components (as of 2025-12-31)

Cash & Equivalents$90.85M
Accounts Receivable$62.51M
Inventory$48.43M
Current Liabilities$77.80M
Long-term Debt$525,000
Op. Lease Liability$16.92M
Finance LeaseN/A
Shares Outstanding128.6M

Explore all 243 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2025-12-31$90.85M$62.51M$48.43MN/A$77.80M$525,000$16.92MN/A
2025-09-30$93.28M$56.63M$51.65MN/A$75.21M$655,000$16.59MN/A
2025-06-30$75.47M$56.23M$49.49MN/A$73.27M$791,000$17.44MN/A
2025-03-31$95.30M$55.03M$45.35MN/A$67.69M$918,000$10.99MN/A
2024-12-31$98.72M$60.59M$43.89MN/A$67.66M$1.05M$11.31MN/A
2024-09-30$162.27M$52.63M$46.80MN/A$62.80M$1.24M$11.29MN/A
2024-06-30$177.89M$44.64M$50.07MN/A$52.38M$1.33M$10.52MN/A
2024-03-31$168.79M$50.31M$54.74MN/A$55.57M$1.48M$10.98MN/A

Comments

SEC Filings

PeriodFormFiledLink
2025-12-31 10-K 2026-02-26 View
2025-09-30 10-Q 2025-11-05 View
2025-06-30 10-Q 2025-08-06 View
2025-03-31 10-Q 2025-05-08 View
2024-12-31 10-K 2025-02-28 View
2024-09-30 10-Q 2024-11-07 View
2024-06-30 10-Q 2024-08-06 View
2024-03-31 10-Q 2024-05-08 View

Community Notes

Loading notes...

Questions

Loading questions...